{"transactions":[{"id":4634257,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":86779,"kind":"person","name":"Smith Nancy Freda","position":1,"cik":"0002019811","reported_name":"Smith Nancy Freda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-10-03T00:18:33.000Z","date":"2026-09-22","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":25000,"derivative":{"exercise_price":1,"expiration_date":"2036-09-22","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-26-106400","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019811/000121390026106400/ownership.xml","form_type":"4"}},{"id":728670,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Series B Warrant (right to buy)","published_at":"2026-06-23T20:56:17.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 24, 2026, Factor Biosciences Inc. (\"Factor\") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. (\"Common Stock\") and warrants to purchase 462,964 shares of Common Stock (the \"Warrants\"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor."}],"balance_after":231482,"derivative":{"exercise_price":2.16,"underlying":"Common Stock","underlying_shares":231482},"source":{"system":"sec-edgar","filing":"0001193125-26-279703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526279703/ownership.xml","form_type":"4"}},{"id":728669,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Series A Warrant (right to buy)","published_at":"2026-06-23T20:56:17.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 24, 2026, Factor Biosciences Inc. (\"Factor\") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. (\"Common Stock\") and warrants to purchase 462,964 shares of Common Stock (the \"Warrants\"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor."}],"balance_after":231482,"derivative":{"exercise_price":2.16,"underlying":"Common Stock","underlying_shares":231482},"source":{"system":"sec-edgar","filing":"0001193125-26-279703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526279703/ownership.xml","form_type":"4"}},{"id":728668,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-06-23T20:56:17.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"price":2.16,"value":500001.12,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 24, 2026, Factor Biosciences Inc. (\"Factor\") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. (\"Common Stock\") and warrants to purchase 462,964 shares of Common Stock (the \"Warrants\"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor."}],"balance_after":231482,"source":{"system":"sec-edgar","filing":"0001193125-26-279703","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526279703/ownership.xml","form_type":"4"}},{"id":734439,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":37325,"kind":"person","name":"Yee John D.","position":1,"cik":"0001926290","reported_name":"Yee John D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T23:24:54.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":25000,"derivative":{"exercise_price":1.27,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-274545","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1926290/000119312526274545/ownership.xml","form_type":"4"}},{"id":745838,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":40392,"kind":"person","name":"Richey William Drake","position":1,"cik":"0002139522","reported_name":"Richey William Drake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:17:42.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":25000,"derivative":{"exercise_price":1.27,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-262257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526262257/ownership.xml","form_type":"4"}},{"id":819015,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-02T21:00:36.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":22000,"derivative":{"exercise_price":1.64,"expiration_date":"2036-03-30","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001947673-26-000002","document":"form4-04022026_050423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000194767326000002/form4-04022026_050423.xml","form_type":"4"}},{"id":819014,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-02T21:00:35.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":140000,"derivative":{"exercise_price":1.64,"expiration_date":"2036-03-30","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001871423-26-000002","document":"form4-04022026_050421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000187142326000002/form4-04022026_050421.xml","form_type":"4"}},{"id":828080,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-25T21:32:36.000Z","date":"2026-03-24","kind":"purchase","planned":false,"acquired":true,"shares":231482,"price":2.16,"value":500001.12,"ownership":{"direct":false,"nature":"By Factor Bioscience Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Factor Bioscience Inc. (\"Factor\"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein."}],"balance_after":231482,"source":{"system":"sec-edgar","filing":"0001931356-26-000011","document":"form4-03252026_090332.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000193135626000011/form4-03252026_090332.xml","form_type":"4"}},{"id":915789,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":35910,"kind":"person","name":"Angel Matthew","position":1,"cik":"0001931356","reported_name":"Angel Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-06T21:26:13.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":269621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":269621,"derivative":{"exercise_price":2.38,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":269621},"source":{"system":"sec-edgar","filing":"0001931356-26-000006","document":"form4-02062026_090210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000193135626000006/form4-02062026_090210.xml","form_type":"4"}},{"id":928836,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T21:30:08.000Z","date":"2026-01-27","kind":"grant","planned":false,"acquired":true,"shares":1230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":1230,"derivative":{"exercise_price":2.94,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":1230},"source":{"system":"sec-edgar","filing":"0001321402-26-000003","document":"form4-01282026_040105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000132140226000003/form4-01282026_040105.xml","form_type":"4"}},{"id":929176,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":26993,"kind":"person","name":"Pellizzari Christine A","position":1,"cik":"0001127430","reported_name":"Pellizzari Christine A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T21:30:06.000Z","date":"2026-01-27","kind":"grant","planned":false,"acquired":true,"shares":1230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":1230,"derivative":{"exercise_price":2.94,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":1230},"source":{"system":"sec-edgar","filing":"0001127430-26-000002","document":"form4-01282026_040103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1127430/000112743026000002/form4-01282026_040103.xml","form_type":"4"}},{"id":929093,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68605,"kind":"person","name":"Simantov Ronit","position":1,"cik":"0001871563","reported_name":"Simantov Ronit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T16:30:13.000Z","date":"2026-01-27","kind":"grant","planned":false,"acquired":true,"shares":1230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":1230,"derivative":{"exercise_price":2.94,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":1230},"source":{"system":"sec-edgar","filing":"0001871563-26-000002","document":"form4-01282026_040107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871563/000187156326000002/form4-01282026_040107.xml","form_type":"4"}},{"id":928843,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68581,"kind":"person","name":"NICHOL GEOFFREY","position":1,"cik":"0001214505","reported_name":"NICHOL GEOFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-28T16:30:08.000Z","date":"2026-01-27","kind":"grant","planned":false,"acquired":true,"shares":1230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":1230,"derivative":{"exercise_price":2.94,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":1230},"source":{"system":"sec-edgar","filing":"0001214505-26-000003","document":"form4-01282026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214505/000121450526000003/form4-01282026_040101.xml","form_type":"4"}},{"id":1309789,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-06T22:00:25.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service."}],"balance_after":550000,"derivative":{"exercise_price":0.86,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0001415889-25-000807","document":"form4-01062025_050116.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588925000807/form4-01062025_050116.xml","form_type":"4"}},{"id":1309788,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-06T22:00:23.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service."}],"balance_after":270000,"derivative":{"exercise_price":0.86,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001415889-25-000806","document":"form4-01062025_050114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588925000806/form4-01062025_050114.xml","form_type":"4"}},{"id":1309787,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-06T22:00:22.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service."}],"balance_after":30000,"derivative":{"exercise_price":0.86,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-000808","document":"form4-01062025_050118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588925000808/form4-01062025_050118.xml","form_type":"4"}},{"id":1309786,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-06T22:00:20.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service."}],"balance_after":200000,"derivative":{"exercise_price":0.86,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-25-000805","document":"form4-01062025_050112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588925000805/form4-01062025_050112.xml","form_type":"4"}},{"id":1436058,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88365,"kind":"organization","name":"Versant Ventures IV, LLC","position":7,"cik":"0001456589","reported_name":"Versant Ventures IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88366,"kind":"organization","name":"Versant Venture Capital IV, L.P.","position":8,"cik":"0001456590","reported_name":"Versant Venture Capital IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88367,"kind":"organization","name":"Versant Side Fund IV, L.P.","position":9,"cik":"0001456591","reported_name":"Versant Side Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:33:19.000Z","date":"2024-08-12","kind":"sale","planned":false,"acquired":false,"shares":387999,"price":1.1005,"value":426992.8995,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":209941,"source":{"system":"sec-edgar","filing":"0000950170-24-095675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777652/000095017024095675/ownership.xml","form_type":"4"}},{"id":1436057,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74644,"kind":"organization","name":"Versant Ventures VI GP, L.P.","position":2,"cik":"0001777654","reported_name":"Versant Ventures VI GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74645,"kind":"organization","name":"Versant Ventures VI GP-GP, LLC","position":3,"cik":"0001777652","reported_name":"Versant Ventures VI GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74646,"kind":"organization","name":"Versant Vantage II, L.P.","position":4,"cik":"0001832235","reported_name":"Versant Vantage II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74647,"kind":"organization","name":"Versant Vantage II GP, L.P.","position":5,"cik":"0001839790","reported_name":"Versant Vantage II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74648,"kind":"organization","name":"Versant Vantage II GP-GP, LLC","position":6,"cik":"0001839789","reported_name":"Versant Vantage II GP-GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88365,"kind":"organization","name":"Versant Ventures IV, LLC","position":7,"cik":"0001456589","reported_name":"Versant Ventures IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88366,"kind":"organization","name":"Versant Venture Capital IV, L.P.","position":8,"cik":"0001456590","reported_name":"Versant Venture Capital IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88367,"kind":"organization","name":"Versant Side Fund IV, L.P.","position":9,"cik":"0001456591","reported_name":"Versant Side Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:33:19.000Z","date":"2024-08-08","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":1.3501,"value":540040.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":597940,"source":{"system":"sec-edgar","filing":"0000950170-24-095675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777652/000095017024095675/ownership.xml","form_type":"4"}},{"id":1458162,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-08T20:15:11.000Z","date":"2024-07-03","kind":"purchase","planned":false,"acquired":true,"shares":35000,"price":2.11,"value":73850.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 11,376 shares acquired under the Issuer's stock purchase plan."}],"balance_after":46376,"source":{"system":"sec-edgar","filing":"0001415889-24-019339","document":"form4-07082024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588924019339/form4-07082024_040701.xml","form_type":"4"}},{"id":1459390,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-03T23:35:42.000Z","date":"2024-07-02","kind":"purchase","planned":false,"acquired":true,"shares":4672,"price":2.13,"value":9951.36,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,000 shares acquired under the Issuer's stock purchase plan."}],"balance_after":9573,"source":{"system":"sec-edgar","filing":"0001415889-24-019279","document":"form4-07032024_110739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588924019279/form4-07032024_110739.xml","form_type":"4"}},{"id":1462166,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Common Stock","published_at":"2024-07-02T20:15:14.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":2.16,"value":16200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 14,668 shares acquired under the Issuer's stock purchase plan."}],"balance_after":22168,"source":{"system":"sec-edgar","filing":"0001415889-24-018866","document":"form4-07022024_040706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000141588924018866/form4-07022024_040706.xml","form_type":"4"}},{"id":1479537,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":26993,"kind":"person","name":"Pellizzari Christine A","position":1,"cik":"0001127430","reported_name":"Pellizzari Christine A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T22:05:11.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":3.03,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001415889-24-017012","document":"form4-06142024_060608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1127430/000141588924017012/form4-06142024_060608.xml","form_type":"4"}},{"id":1478690,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T22:05:05.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":3.03,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001415889-24-017009","document":"form4-06142024_060601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000141588924017009/form4-06142024_060601.xml","form_type":"4"}},{"id":1478724,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68581,"kind":"person","name":"NICHOL GEOFFREY","position":1,"cik":"0001214505","reported_name":"NICHOL GEOFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T18:05:09.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":3.03,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001415889-24-017011","document":"form4-06142024_060605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214505/000141588924017011/form4-06142024_060605.xml","form_type":"4"}},{"id":1479344,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68605,"kind":"person","name":"Simantov Ronit","position":1,"cik":"0001871563","reported_name":"Simantov Ronit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T18:05:07.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":16000,"derivative":{"exercise_price":3.03,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001415889-24-017010","document":"form4-06142024_060603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871563/000141588924017010/form4-06142024_060603.xml","form_type":"4"}},{"id":1685201,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-05T21:41:03.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service."}],"balance_after":250000,"derivative":{"exercise_price":4.66,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-24-001040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919124001040/doc4.xml","form_type":"4"}},{"id":1685200,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-05T21:40:01.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service."}],"balance_after":100000,"derivative":{"exercise_price":4.66,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-24-001038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919124001038/doc4.xml","form_type":"4"}},{"id":1685199,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-05T21:39:05.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service."}],"balance_after":26500,"derivative":{"exercise_price":4.66,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":26500},"source":{"system":"sec-edgar","filing":"0001209191-24-001036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919124001036/doc4.xml","form_type":"4"}},{"id":1685198,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Strategy and Finance"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-05T21:38:19.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service."}],"balance_after":40000,"derivative":{"exercise_price":4.66,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-24-001035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919124001035/doc4.xml","form_type":"4"}},{"id":1760491,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-13T20:41:32.000Z","date":"2023-10-11","kind":"grant","planned":false,"acquired":true,"shares":725000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":725000,"derivative":{"exercise_price":9.77,"expiration_date":"2033-10-10","underlying":"Common Stock","underlying_shares":725000},"source":{"system":"sec-edgar","filing":"0001209191-23-052783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123052783/doc4.xml","form_type":"4"}},{"id":1760490,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-13T20:39:59.000Z","date":"2023-10-11","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":55000,"derivative":{"exercise_price":9.77,"expiration_date":"2033-10-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-23-052782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123052782/doc4.xml","form_type":"4"}},{"id":1760489,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-13T20:39:13.000Z","date":"2023-10-11","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":325000,"derivative":{"exercise_price":9.77,"expiration_date":"2033-10-10","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001209191-23-052781","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123052781/doc4.xml","form_type":"4"}},{"id":1760488,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Strategy and Finance"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-10-13T20:38:37.000Z","date":"2023-10-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":9.77,"expiration_date":"2033-10-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-052780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123052780/doc4.xml","form_type":"4"}},{"id":1849090,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T20:53:55.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":8200,"derivative":{"exercise_price":1.42,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001209191-23-038453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000120919123038453/doc4.xml","form_type":"4"}},{"id":1850162,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":26993,"kind":"person","name":"Pellizzari Christine A","position":1,"cik":"0001127430","reported_name":"Pellizzari Christine A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T20:48:09.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":8200,"derivative":{"exercise_price":1.42,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001209191-23-038443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1127430/000120919123038443/doc4.xml","form_type":"4"}},{"id":1849144,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68581,"kind":"person","name":"NICHOL GEOFFREY","position":1,"cik":"0001214505","reported_name":"NICHOL GEOFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T16:50:35.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":8200,"derivative":{"exercise_price":1.42,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001209191-23-038448","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214505/000120919123038448/doc4.xml","form_type":"4"}},{"id":1849930,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68605,"kind":"person","name":"Simantov Ronit","position":1,"cik":"0001871563","reported_name":"Simantov Ronit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T16:46:11.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":8200,"derivative":{"exercise_price":1.42,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001209191-23-038440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871563/000120919123038440/doc4.xml","form_type":"4"}},{"id":2061793,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-06T01:02:36.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":69700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service."}],"balance_after":69700,"derivative":{"exercise_price":1.23,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":69700},"source":{"system":"sec-edgar","filing":"0001209191-23-002148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123002148/doc4.xml","form_type":"4"}},{"id":2061791,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-06T01:00:46.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":177300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service."}],"balance_after":177300,"derivative":{"exercise_price":1.23,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":177300},"source":{"system":"sec-edgar","filing":"0001209191-23-002144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123002144/doc4.xml","form_type":"4"}},{"id":2061792,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Strategy and Finance"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-06T00:59:15.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":38425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service."}],"balance_after":38425,"derivative":{"exercise_price":1.23,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":38425},"source":{"system":"sec-edgar","filing":"0001209191-23-002142","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123002142/doc4.xml","form_type":"4"}},{"id":2061794,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-06T00:57:06.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":20300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service."}],"balance_after":20300,"derivative":{"exercise_price":1.23,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":20300},"source":{"system":"sec-edgar","filing":"0001209191-23-002141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919123002141/doc4.xml","form_type":"4"}},{"id":2062657,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-05T20:01:41.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":102700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service."}],"balance_after":102700,"derivative":{"exercise_price":1.23,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":102700},"source":{"system":"sec-edgar","filing":"0001209191-23-002146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000120919123002146/doc4.xml","form_type":"4"}},{"id":2143706,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":54206,"kind":"person","name":"Trojanowski Justin","position":1,"cik":"0001947673","reported_name":"Trojanowski Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-10-04T12:01:48.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in 48 equal monthly installments commencing on November 3, 2022, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":2500,"derivative":{"exercise_price":1.85,"expiration_date":"2032-10-02","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-22-052025","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919122052025/doc4.xml","form_type":"4"}},{"id":2223811,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Strategy and Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:35:43.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":51270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":51270,"derivative":{"exercise_price":2.35,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":51270},"source":{"system":"sec-edgar","filing":"0001179110-22-003401","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911022003401/edgar.xml","form_type":"4"}},{"id":2223810,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:32:59.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":55680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":55680,"derivative":{"exercise_price":2.35,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":55680},"source":{"system":"sec-edgar","filing":"0001179110-22-003400","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911022003400/edgar.xml","form_type":"4"}},{"id":2223809,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:29:02.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":173533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":173533,"derivative":{"exercise_price":2.35,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":173533},"source":{"system":"sec-edgar","filing":"0001179110-22-003398","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911022003398/edgar.xml","form_type":"4"}},{"id":2224431,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":26993,"kind":"person","name":"Pellizzari Christine A","position":1,"cik":"0001127430","reported_name":"Pellizzari Christine A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:17:58.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001179110-22-003383","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1127430/000117911022003383/edgar.xml","form_type":"4"}},{"id":2223806,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:13:39.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001179110-22-003378","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911022003378/edgar.xml","form_type":"4"}},{"id":2223924,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:09:25.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001179110-22-003376","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000117911022003376/edgar.xml","form_type":"4"}},{"id":2224334,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T16:38:14.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":8477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":8477,"derivative":{"exercise_price":2.35,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":8477},"source":{"system":"sec-edgar","filing":"0001179110-22-003402","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000117911022003402/edgar.xml","form_type":"4"}},{"id":2224101,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T16:31:29.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":87801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":87801,"derivative":{"exercise_price":2.35,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":87801},"source":{"system":"sec-edgar","filing":"0001179110-22-003399","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000117911022003399/edgar.xml","form_type":"4"}},{"id":2223940,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68581,"kind":"person","name":"NICHOL GEOFFREY","position":1,"cik":"0001214505","reported_name":"NICHOL GEOFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T16:16:44.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001179110-22-003380","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214505/000117911022003380/edgar.xml","form_type":"4"}},{"id":2224341,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68605,"kind":"person","name":"Simantov Ronit","position":1,"cik":"0001871563","reported_name":"Simantov Ronit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T16:11:02.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date."}],"balance_after":3500,"derivative":{"exercise_price":2.08,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001179110-22-003377","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871563/000117911022003377/edgar.xml","form_type":"4"}},{"id":2283810,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T21:49:06.000Z","date":"2022-04-29","kind":"purchase","acquired":true,"shares":2118644,"price":2.36,"value":4999999.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. (\"Vantage II\") and certain other investors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by Vantage II. Versant Vantage II GP, L.P. (\"Vantage II GP\") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC (\"Vantage II GP-GP\") is the general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":2118644,"source":{"system":"sec-edgar","filing":"0000899243-22-016387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000089924322016387/doc4.xml","form_type":"4"}},{"id":2437742,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-01-11T18:36:17.000Z","date":"2022-01-07","kind":"purchase","acquired":true,"shares":2000,"price":4.78,"value":9560.0,"ownership":{"direct":true},"balance_after":113343,"source":{"system":"sec-edgar","filing":"0001209191-22-002963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000120919122002963/doc4.xml","form_type":"4"}},{"id":2438675,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-10T23:37:47.000Z","date":"2022-01-06","kind":"purchase","acquired":true,"shares":1700,"price":4.8048,"value":8168.16,"ownership":{"direct":true},"balance_after":1901,"source":{"system":"sec-edgar","filing":"0001209191-22-002753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919122002753/doc4.xml","form_type":"4"}},{"id":2441058,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Strategy and Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-07T00:26:13.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service."}],"balance_after":19500,"derivative":{"exercise_price":5.45,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001209191-22-002251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919122002251/doc4.xml","form_type":"4"}},{"id":2441056,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-07T00:25:12.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service."}],"balance_after":29000,"derivative":{"exercise_price":5.45,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001209191-22-002249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919122002249/doc4.xml","form_type":"4"}},{"id":2441057,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-07T00:23:57.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":94500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service."}],"balance_after":94500,"derivative":{"exercise_price":5.45,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":94500},"source":{"system":"sec-edgar","filing":"0001209191-22-002247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919122002247/doc4.xml","form_type":"4"}},{"id":2441831,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-06T19:26:58.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service."}],"balance_after":6500,"derivative":{"exercise_price":5.45,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001209191-22-002253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000120919122002253/doc4.xml","form_type":"4"}},{"id":2441561,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-06T19:22:32.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":53100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service."}],"balance_after":53100,"derivative":{"exercise_price":5.45,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":53100},"source":{"system":"sec-edgar","filing":"0001209191-22-002245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000120919122002245/doc4.xml","form_type":"4"}},{"id":2560731,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-23T23:56:05.000Z","date":"2021-09-21","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on July 1, 2022 and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":6635,"derivative":{"exercise_price":15.15,"expiration_date":"2031-09-20","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001209191-21-057511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000120919121057511/doc4.xml","form_type":"4"}},{"id":2564288,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":26993,"kind":"person","name":"Pellizzari Christine A","position":1,"cik":"0001127430","reported_name":"Pellizzari Christine A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-21T00:29:47.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008868","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1127430/000117911021008868/edgar.xml","form_type":"4/A","original_submission_date":"2021-07-06"}},{"id":2563802,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-21T00:13:06.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008867","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911021008867/edgar.xml","form_type":"4/A","original_submission_date":"2021-07-06"}},{"id":2563801,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-21T00:10:08.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is amanager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed anadmission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008866","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911021008866/edgar.xml","form_type":"4/A","original_submission_date":"2021-07-06"}},{"id":2563877,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68581,"kind":"person","name":"NICHOL GEOFFREY","position":1,"cik":"0001214505","reported_name":"NICHOL GEOFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-20T20:34:43.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008869","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214505/000117911021008869/edgar.xml","form_type":"4/A","original_submission_date":"2021-07-06"}},{"id":2608722,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68605,"kind":"person","name":"Simantov Ronit","position":1,"cik":"0001871563","reported_name":"Simantov Ronit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-10T19:05:24.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three  (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."}],"balance_after":6635,"derivative":{"exercise_price":13.6,"expiration_date":"2031-08-05","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008097","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871563/000117911021008097/edgar.xml","form_type":"4"}},{"id":2633840,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":29252,"kind":"person","name":"Maestas Nicholas","position":1,"cik":"0001871423","reported_name":"Maestas Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Strategy and Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-14T20:27:15.000Z","date":"2021-07-12","kind":"grant","acquired":true,"shares":23225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 12, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":23225,"derivative":{"exercise_price":24.19,"expiration_date":"2031-07-11","underlying":"Common Stock","underlying_shares":23225},"source":{"system":"sec-edgar","filing":"0001567619-21-013380","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000156761921013380/doc1.xml","form_type":"4"}},{"id":2640535,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T22:05:53.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is a manager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001140361-21-023544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121023544/form4.xml","form_type":"4"}},{"id":2640534,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T22:01:21.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001140361-21-023542","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121023542/form4.xml","form_type":"4"}},{"id":2641747,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":26993,"kind":"person","name":"Pellizzari Christine A","position":1,"cik":"0001127430","reported_name":"Pellizzari Christine A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T21:52:30.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001140361-21-023538","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1127430/000114036121023538/form4.xml","form_type":"4"}},{"id":2640783,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":68581,"kind":"person","name":"NICHOL GEOFFREY","position":1,"cik":"0001214505","reported_name":"NICHOL GEOFFREY","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T17:56:28.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001140361-21-023540","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214505/000114036121023540/form4.xml","form_type":"4"}},{"id":2649473,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T20:16:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":540231,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service."}],"balance_after":540231,"derivative":{"exercise_price":26.4,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":540231},"source":{"system":"sec-edgar","filing":"0001140361-21-022931","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022931/form4.xml","form_type":"4"}},{"id":2649472,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T20:16:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":3018,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions."}],"balance_after":3018,"derivative":{"exercise_price":10.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":3018},"source":{"system":"sec-edgar","filing":"0001140361-21-022931","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022931/form4.xml","form_type":"4"}},{"id":2649471,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T20:16:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":61945,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares underlying this option vest on November 16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. Notwithstanding the foregoing, if within three months prior to or 12 months following a change in control Tempest terminates the reporting person's employment without cause or the reporting person resigns for good reason, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions."}],"balance_after":61945,"derivative":{"exercise_price":5.9,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":61945},"source":{"system":"sec-edgar","filing":"0001140361-21-022931","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022931/form4.xml","form_type":"4"}},{"id":2649470,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84386,"kind":"person","name":"Whiting Samuel","position":1,"cik":"0001870373","reported_name":"Whiting Samuel","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-30T20:16:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":201,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""}],"balance_after":201,"source":{"system":"sec-edgar","filing":"0001140361-21-022931","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022931/form4.xml","form_type":"4"}},{"id":2651259,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-30T01:56:06.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":579710,"ownership":{"direct":false,"nature":"By Quan Venture Fund I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This amount includes 104,176 shares that were acquired upon conversion of 3,235,294 shares of Tempest, which Quan Capital agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record held by Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of any pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":579710,"source":{"system":"sec-edgar","filing":"0001140361-21-022786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022786/form4.xml","form_type":"4"}},{"id":2651410,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:55:16.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":4830,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service."}],"balance_after":4830,"derivative":{"exercise_price":10.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":4830},"source":{"system":"sec-edgar","filing":"0001140361-21-022785","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000114036121022785/form4.xml","form_type":"4"}},{"id":2651409,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:55:16.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":9660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of February 20, 2020, subject to the reporting person's continued service."}],"balance_after":9660,"derivative":{"exercise_price":5.9,"expiration_date":"2030-03-29","underlying":"Common Stock","underlying_shares":9660},"source":{"system":"sec-edgar","filing":"0001140361-21-022785","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000114036121022785/form4.xml","form_type":"4"}},{"id":2651408,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":19876,"kind":"person","name":"RAAB MICHAEL","position":1,"cik":"0001321402","reported_name":"RAAB MICHAEL","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:55:16.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":16784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of January 1, 2019, subject to the reporting person's continued service. These stock options provide for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase."}],"balance_after":16784,"derivative":{"exercise_price":4.97,"expiration_date":"2028-12-18","underlying":"Common Stock","underlying_shares":16784},"source":{"system":"sec-edgar","filing":"0001140361-21-022785","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321402/000114036121022785/form4.xml","form_type":"4"}},{"id":2651258,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:54:45.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":1982250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service."}],"balance_after":1982250,"derivative":{"exercise_price":26.4,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":1982250},"source":{"system":"sec-edgar","filing":"0001140361-21-022783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022783/form4.xml","form_type":"4"}},{"id":2651257,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:54:45.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":8050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions."}],"balance_after":8050,"derivative":{"exercise_price":10.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":8050},"source":{"system":"sec-edgar","filing":"0001140361-21-022783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022783/form4.xml","form_type":"4"}},{"id":2651256,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:54:45.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":70256,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of February 20, 2020, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions."}],"balance_after":70256,"derivative":{"exercise_price":5.9,"expiration_date":"2030-03-29","underlying":"Common Stock","underlying_shares":70256},"source":{"system":"sec-edgar","filing":"0001140361-21-022783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022783/form4.xml","form_type":"4"}},{"id":2651255,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":84387,"kind":"person","name":"Brady Stephen R","position":1,"cik":"0001606241","reported_name":"Brady Stephen R","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T01:54:45.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":110432,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares underlying this option vested on September 9, 2020, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. Notwithstanding the foregoing, 100% of the unvested shares subject to this option vest immediately on the earliest of (i) the date that is 12 months following a change in control of the Issuer, (ii) the date the Issuer terminates the reporting person's status as a service provider upon or following the closing of the change in control for any reason other than cause or the reporting person's death or disability, in each case within the period beginning three months before and ending 12 months after the closing of the change in control, and (iii) the date the reporting person terminates his status as a service provider for good reason within the period beginning three months before and ending 12 months after the closing of the change in control (the \"Brady Double-Trigger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"If the successor corporation in a change in control does not assume the Brady Double-Trigger obligation, 100% of the unvested shares subject to this option will vest immediately prior to such change in control."}],"balance_after":110432,"derivative":{"exercise_price":4.97,"expiration_date":"2029-09-15","underlying":"Common Stock","underlying_shares":110432},"source":{"system":"sec-edgar","filing":"0001140361-21-022783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022783/form4.xml","form_type":"4"}},{"id":2651254,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-30T01:54:43.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":7377,"ownership":{"direct":false,"nature":"By Versant Side Fund IV, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"This amount includes 1,897 shares that were acquired upon conversion of 58,927 shares of Tempest, which VSF IV agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These shares are held of record by Versant Side Fund IV, L.P. (\"VSF IV\"). VV IV is the general partner of VSF IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by Versant Side Fund IV, L.P. (\"VSF IV\"). VV IV is the general partner of VSF IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VSF IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":7377,"source":{"system":"sec-edgar","filing":"0001140361-21-022782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022782/form4.xml","form_type":"4"}},{"id":2651253,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-30T01:54:43.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":1171094,"ownership":{"direct":false,"nature":"By Versant Venture Capital IV, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This amount includes 301,161 shares that were acquired upon conversion of 9,352,838 shares of Tempest, which VVC IV agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are held of record by Versant Venture Capital IV, L.P. (\"VVC IV\"). Versant Ventures IV, LLC (\"VV IV\") is the general partner of VVC IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VVC IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by Versant Venture Capital IV, L.P. (\"VVC IV\"). Versant Ventures IV, LLC (\"VV IV\") is the general partner of VVC IV. The Reporting Person is a managing member of VV IV and may be deemed to share voting and dispositive power over the shares held by VVC IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":1171094,"source":{"system":"sec-edgar","filing":"0001140361-21-022782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022782/form4.xml","form_type":"4"}},{"id":2651252,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-06-30T01:54:43.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":997940,"ownership":{"direct":false,"nature":"By Versant Venture Capital VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held of record held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI.  The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI.  The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":997940,"source":{"system":"sec-edgar","filing":"0001140361-21-022782","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022782/form4.xml","form_type":"4"}},{"id":2651738,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:55:26.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service."}],"balance_after":1000000,"derivative":{"exercise_price":26.4,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001140361-21-022784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000114036121022784/form4.xml","form_type":"4"}},{"id":2651737,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:55:26.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":8050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions."}],"balance_after":8050,"derivative":{"exercise_price":10.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":8050},"source":{"system":"sec-edgar","filing":"0001140361-21-022784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000114036121022784/form4.xml","form_type":"4"}},{"id":2651736,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:55:26.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":45988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of February 20, 2020, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions."}],"balance_after":45988,"derivative":{"exercise_price":5.9,"expiration_date":"2030-03-29","underlying":"Common Stock","underlying_shares":45988},"source":{"system":"sec-edgar","filing":"0001140361-21-022784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000114036121022784/form4.xml","form_type":"4"}},{"id":2651735,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:55:26.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":36263,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares underlying this option vest upon Closing."}],"balance_after":36263,"derivative":{"exercise_price":4.97,"expiration_date":"2028-10-02","underlying":"Common Stock","underlying_shares":36263},"source":{"system":"sec-edgar","filing":"0001140361-21-022784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000114036121022784/form4.xml","form_type":"4"}},{"id":2651734,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":120921,"kind":"person","name":"Dubensky Thomas W.","position":1,"cik":"0001635590","reported_name":"Dubensky Thomas W.","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2021-06-29T21:55:26.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":111343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""}],"balance_after":111343,"source":{"system":"sec-edgar","filing":"0001140361-21-022784","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635590/000114036121022784/form4.xml","form_type":"4"}},{"id":2652168,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":48535,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service."}],"balance_after":48535,"derivative":{"exercise_price":26.4,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":48535},"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2652167,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":1234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service."}],"balance_after":1234,"derivative":{"exercise_price":10.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":1234},"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2652166,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":4830,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares underlying this option vest on November 16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":4830,"derivative":{"exercise_price":5.9,"expiration_date":"2030-11-15","underlying":"Common Stock","underlying_shares":4830},"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2652165,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":125957,"kind":"person","name":"Lorenzo Pierre","position":1,"cik":"0001869915","reported_name":"Lorenzo Pierre","relationship":{"officer":true,"officer_title":"Corporate Controller"}}],"security":"Common Stock","published_at":"2021-06-29T21:53:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":53,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the \"Exchange Ratio\"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""}],"balance_after":53,"source":{"system":"sec-edgar","filing":"0001140361-21-022781","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869915/000114036121022781/form4.xml","form_type":"4"}},{"id":2777701,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":124004,"kind":"person","name":"Owens Julia C.","position":1,"cik":"0001760219","reported_name":"Owens Julia C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chair"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-19T16:47:56.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the shares subject to this option shall vest on February 1, 2022, and one twenty-fourth (1/24th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control."}],"balance_after":24000,"derivative":{"exercise_price":2.29,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001544227-21-000013","document":"wf-form4_161618685991338.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760219/000154422721000013/wf-form4_161618685991338.xml","form_type":"4"}},{"id":2822539,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":65257,"kind":"person","name":"Minai-Azary Jennifer Lynn","position":1,"cik":"0001844398","reported_name":"Minai-Azary Jennifer Lynn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-02T17:19:30.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control."}],"balance_after":110000,"derivative":{"exercise_price":2.06,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001544227-21-000011","document":"wf-form4_161472352776309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1844398/000154422721000011/wf-form4_161472352776309.xml","form_type":"4"}}],"next_cursor":"2021-03-02T17:19:30.000000Z,2822539"}